|
 Multisystem inflammatory syndrome (MIS-C) is a rare but severe
condition that shares symptoms with toxic shock and Kawasaki
disease, including fever, rashes, swollen glands and, in severe
cases, heart inflammation.
It has been reported in children and adolescent patients about two
to four weeks after the onset of COVID-19.
With rising COVID-19 cases, there could be an increased occurrence
of MIS-C, but this might not be apparent immediately because of the
delay in development of symptoms, said the report's authors,
including those from the CDC's COVID-19 response team.
In May, the CDC published a health advisory with details of how
MIS-C manifests in patients, and asked clinicians to report
suspected U.S. cases to local and state health departments.
As of July 29, state health departments across the country reported
a total of 570 MIS-C patients diagnosed with the illness from March
2 to July 18.
[to top of second column] |
Among the MIS-C cases, all patients tested positive for COVID-19 and 10 died,
the CDC said in the report.
The data is consistent with two U.S. studies published in June and several
reports of the syndrome among COVID-19 patients in France, Italy, Spain and
Britain. [nL4N2E64AX]
The report, the CDC said, highlights the need for greater awareness among
healthcare providers, as distinguishing patients with MIS-C from those with
acute COVID-19 and other hyperinflammatory conditions is critical for early
recognition, early diagnosis, and prompt treatment.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Tom Brown)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
